The article discusses a study entitled "Interleukin-25 induces type 2 cytokine production in a steroid-resistant interleukin-17RB+ myeloid population that exacerbates asthmatic pathology," by B. C. Petersen and colleagues, which suggests that T2M cells may represent a new therapeutic target for the said disease.